

1)	Leading Products	YR06 JAN-JUN No. of Prescriptions (Thousands)
1	NORVASC	42,430
2	MUCODYNE	33,517
3	LOXONIN	32,454
4	BAYASPIRIN	27,981
5	MUCOSTA	26,604
6	BLOPRESS	26,142
7	GASTER	22,837
8	SELBEX	22,023
9	AMLODIN	20,051
10	LIPITOR	20,014

Copyright IMS Japan KK, 2006
 Source: IMS Japan Medical Data Index
 Reprinted with permission

2)	Leading Therapy Classes	YR06 JAN-JUN No of Prescriptions (Thousands)
1	A02 ANTACIDS, ANTIFLATULENTS AND ANTI-ULCERANTS	211,902
2	N05 PSYCHOLEPTICS	169,022
3	R05 COUGH & COLD PREPARATIONS	142,846
4	C08 CALCIUM ANTAGONISTS	132,889
5	J01 SYSTEMIC ANTIBACTERIALS	120,991
6	S01 OPHTHALMOLOGICALS	100,627
7	C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	100,541
8	M01 ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS	94,957
9	C10 LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS	86,967
10	R03 ANTI-ASTHMA AND COPD PRODUCTS	83,376

Copyright IMS Japan KK, 2006
 Source: IMS Japan Medical Data Index
 Reprinted with permission

3)	Leading Disease Classes	YR06 JAN-JUN No. of Prescriptions (Thousands)
1	HYPERTENSIVE DISEASE	294,458
2	ACUTE UPPER RESPIRATORY INFECTION	208,164
3	ESOPHAGUS, STOMACH AND DUODENAL DISEASE	160,329
4	CHRONIC LOWER RESPIRATORY DISEASE	118,435
5	METABOLIC DISORDERS	98,687
6	EPISODIC DISEASE	97,129
7	DIABETES MELLITUS	83,277
8	OTHER ACUTE LOWER RESPIRATORY INFECTION	81,915
9	OTHER DISEASE OF INTESTINES	81,773
10	DERMATITIS & ECZEMA	77,207

Copyright IMS Japan KK, 2006
Source: IMS Japan Medical Data Index
Reprinted with permission



IMS Japan Top-line Data Release to the Media

Brief notes on First-half (Jan-June) 2006 top-line medical (RX) data

● **Leading Products**

The top four products for the first half of this year are as follows:

1st Norvasc (number of prescriptions: 42.43 million), 2nd Mucodyne (number of prescriptions: 33.52 million), 3rd Loxonin (number of prescriptions: 32.45 million) 4th Bayaspirin (number of prescriptions: 27.98 million). The ranking of these products is unchanged from last year.

Among the leading products, three out of the top ten products are drugs for hypertension treatment. These consist of Norvasc in first place (number of prescriptions: 42.43 million), Blopress in sixth place (number of prescriptions: 26.14 million), and Amlodin in ninth place (number of prescriptions: 20.05 million). Although Norvasc and Blopress have almost the same amount of sales, Norvasc prescriptions are still 1.6 times that of Blopress. This disparity is attributable to the higher single day drug price for Blopress.

Meanwhile, antiulcerants and antigastritis agents are among the ten leading products. These consist of Mucosta in fifth place (number of prescriptions: 26.60 million), Gaster in seventh place (number of prescriptions: 22.83 million), and Selbex in eighth place (number of prescriptions: 22.02 million). Mucosta climbed one notch from sixth place in the first half of last year to fifth place.

● **Leading Therapy Classes**

The ten leading therapy classes can be largely classified into four groups: Group 1 consisting of drugs for the alimentary system (A02 antacids, antiflatulents and antiulcerants), Group 2 comprising drugs for the circulatory system (C08 calcium antagonists, C09 agents acting on the renin-angiotensin system, C10 hypolipidaemics/anti-atheroma

preparations), Group 3 consisting of drugs for the psychological disorders (N05 psycholeptics), and Group 4 comprising drugs for the respiratory system (R05 cough and cold preparations, J01 systemic antibiotics, R03 anti-asthma and COPD products).

With respect to drugs for the alimentary system, protective factor enhancers, such as Mucosta and Selbex, are the leading prescriptions. Furthermore, magnesium oxide, which has long been used as an antacid, too is widely prescribed.

Drugs for the circulatory system mainly consist of major products, such as Norvasc, Blopress, Amlodin, Diovan, and Lipitor. However, products launched before 1991, such as Mevalotin, Adalat, Coniel, and Renivace, too are strong.

With respect to drugs for the psychological disorders, the prescription of new types of drugs such as Myslee and Risperdal is increasing alongside old drugs such as Depas, Lendormin and Halcion.

As for drugs for the respiratory system, with the exception of Flomox, these drugs center on drugs which have long been widely used, such as Mucodyne, PL, Asverin, Cefzon, Hokunalin, and Theodur.

Regarding drugs for asthma, Hokunalin, despite being a comparatively old drug launched in September 1981, is the top prescription among R03 anti-asthma and COPD products, surpassing Onon and Theodur.

Also, S01 ophthalmologicals, too, raised one notch from seventh place in the first half of last year to sixth place in the first half of this year. Typical ophthalmologicals include Kary Uni, Cravit, Hyalein, and Xalatan.

● **Leading Disease Classes**

The top three disease classes are hypertensive disease in first place with 294,460 thousand prescriptions, followed by acute upper respiratory disease with 208,160 thousand prescriptions and oesophagus, stomach and duodenal disease with 160,330 thousand prescriptions. This ranking is unchanged from the first half of last year.

Although the same disease classes as last year make up the top ten, the ranking

changed slightly from last year. Metabolic disorders, which ranked seventh last year, jumped to fifth place, and diabetes mellitus, which ranked tenth last year, rose to seventh place. This shows that metabolic diseases ranked higher this year.

Note: The numbers of prescriptions we report in our medical data are estimates and differ from the actual figures.

This report was created by IMS Japan to provide the media with brief explanations around top-line data that IMS Japan periodically releases to the media. This report may not be reprinted, transmitted in any form or by any means, electronic or mechanical, including (but not limited to) photocopy, recording, or any information storage and retrieval system.

©2006 IMS Japan K.K. All rights reserved.